Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus

Introduction: Quick release bromocriptine (BROM-QR), currently approved for glycemic control, reduces the risk of cardiovascular events in adults with type-2 diabetes mellitus (T2DM). This study evaluates the effect of BROM-QR on homocysteine (HOMC) and high sensitive C-reactive protein (hs-CRP), th...

Descripción completa

Detalles Bibliográficos
Autores principales: Niafar, Mitra, Pourafkari, Leili, Shahsavarinia, Kavus, Milanchian, Nushin, Niafar, Farhad, Nader, Nader D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827141/
https://www.ncbi.nlm.nih.gov/pubmed/27069561
http://dx.doi.org/10.15171/jcvtr.2016.02

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827141/
https://www.ncbi.nlm.nih.gov/pubmed/27069561
http://dx.doi.org/10.15171/jcvtr.2016.02

Ejemplares similares